Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. The company is headquartered in Sunnyvale, California and currently employs 474 full-time employees. The company went IPO on 2019-04-04. The firm has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. The company manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.

Industry: Surgical & Medical Instruments & Apparatus Peers: ATRION CORP Avanos Medical Inc Embecta Corp Figs Inc MERIDIAN BIOSCIENCE INC Merit Medical Systems Inc Neogen Corp OrthoPediatrics Corp STAAR Surgical Co